The efficacy of alefacept in the treatment of chronic plaque psoriasis

Journal of Cutaneous Medicine and Surgery

Volumn 8, Issue SUPPL. 2, 2004, Pages 3-9

  Gordon, Kenneth B ^a   Valentine, Jayme ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; ANTIPSORIASIS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; METHOTREXATE; PSORALEN; RETINOID;

CLINICAL TRIAL; CORRELATION ANALYSIS; DEMOGRAPHY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LIVER FUNCTION TEST; MEMORY CELL; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUVA; REVIEW; ULTRAVIOLET B RADIATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PSORIASIS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT FUSION PROTEINS;

EID: 13644250766     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10227-004-9502-3     Document Type: Review

References (17)

1. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137:280-284.
2. Prinz JC. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003; 17:257-270.
3. Gottlieb AB, Bos JD. Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol 2002; 105:105-116.
4. Ellis CN, Krueger GG, et al., for the Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345:248-255.
5. Krueger GG, Papp KA, Stough DB, et al., for the Alefacept Clinical Study Group. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47:821-833.
6. Lebwohl M, Christophers E, Langley R, et al., for the Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139:719-727.
7. Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol 2003; 2:624-628.
8. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157:238-244.
9. Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004; 50:859-866.
10. Gordon KB, Vaishnaw AK, O'Gorman J, et al., for the Alefacept Clinical Study Group. Treatment of psoriasis with alefacept. Correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 2003; 139:1563-1570.
11. Ortonne J-P, Lebwohl M, Griffiths CEM. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol 2003; 13:117-123.
12. Vaishnaw AK, Ticho B. Alefacept is efficacious in a broad spectrum of patients with psoriasis, including those with severe disease. Poster presented at the 61st Annual Meeting of the American Academy of Dermatology, 21-26 March 2003, San Francisco, CA.
13. van de Kerkhof P, Vaishnaw AK, Kragballe K, et al. Alefacept is efficacious in a broad spectrum of patients with psoriasis [abstract]. J Eur Acad Dermatol Venereol 2003; 17(Suppl 1):55.
14. Christophers E, O'Gorman J, Vaishnaw AK. Pooled efficacy of alefacept in psoriasis patients who were refractory to or who had contraindications to other systemic psoriasis treatments or phototherapies. Poster presented at the 9th International Psoriasis Symposium, 18-22 June 2003, New York.
15. Ortonne J-P, Khemis A. Combination therapy with alefacept plus narrowband ultraviolet B light for treatment of psoriasis. Poster presented at the 9th International Psoriasis Symposium, 18-22 June 2003, New York.
16. Koo J. Combination therapy with alefacept plus broadband ultraviolet B light for treatment of psoriasis. Poster presented at the 9th International Psoriasis Symposium, 18-22 June 2003, New York.
17. Krueger GG, Gordon KB, van de Kerkhof P, et al. Repeated courses of IM alefacept in psoriasis: rationale and design of an international study that mimics the clinical practice setting. Poster presented at the International Investigative Dermatology Meeting, 30 April-4 May 2003, Miami Beach, FL.